India's CNBC-TV18 examines implications of country's decision to issue compulsory license for Bayer cancer drug

"India's grant of a compulsory license to Natco for Bayer's kidney-cancer drug Nexavar has sent shockwaves across the globe," but "India has found a backer in the World Health Organization," CNBC-TV18's "moneycontrol.com" reports. "India has taken a good political stand on compulsory license and we respect that move. India is a lead supplier of cheaper generics and this compulsory license will further strengthen it," Nata Menabde a representative for the WHO in India, said, according to the news service. In a video report titled "License to Cure," reporter Archana Shukla interviews a number of experts regarding the global implications of the decision (8/17).